– Review of datasets featured multiple nerve targets and quality of life impacts –
Cleveland, Ohio – July 17, 2023 – SPR Therapeutics had a significant presence at the American Society of Pain & Neuroscience (ASPN) Annual Conference again this year. The event took place in Miami Beach July 13-16 and featured research and clinical discussions from many of the leading voices in pain and neuroscience.
Application of the SPRINT® PNS System was featured in four presentations of new datasets including an oral presentation of Retrospective Review of Real-World Outcomes Across Multiple Health-Related Domains Following 60-day Peripheral Nerve Stimulation Used for Shoulder Pain. This review featured assessment of four domains of health (pain, quality of life, physical function, and sleep) which reflects a more holistic approach evaluating the impact of pain treatment for patients. The real-world evaluation found that 80 percent of patients saw clinically significant improvement in at least one health-related domain and nearly half achieved improvement in all four domains following SPRINT PNS treatment for shoulder pain.
Additional real-world, multi-domain data was shared on the utilization of SPRINT PNS for knee pain, along with new datasets on nerve target specific applications for the groin and cluneal nerves. To view all the material presented at ASPN 2023, visit the SPR website.
“The continued expansion of SPRINT to address pain via a wide range of nerve targets is an exciting development in our continued growth and efforts to restore an improved quality of life to pain sufferers. The multi-domain outcomes are a measure helping illustrate the potential impact the SPRINT System may offer patients,” said Josh Boggs, PhD, Chief Scientific Officer at SPR Therapeutics.
Attendees at ASPN had the opportunity to visit and learn more about the SPRINT PNS System by stopping by the SPR Therapeutics booth along with sponsored lab events and luncheons.
About the SPRINT PNS System
The SPRINT® PNS System, by SPR® Therapeutics, marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line™ PNS option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, is cleared for use up to 60 days, and is recognized by leading pain management centers. Market research indicates that this breakthrough neuromodulation treatment is a patient-preferred alternative to more invasive options.
The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves.
Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.
For additional information regarding safety and efficacy, visit: SPR Safety Information.
About SPR Therapeutics, Inc.
SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally-invasive, drug-free, surgery-free solution to manage their acute and chronic pain.
More information can be found at www.SPRTherapeutics.com.
SPR Contacts:
Michelle McDonald
Vice President – Marketing
844.378.9108
Dave Folkens
Public Relations
612.978.6547
SPR Therapeutics Named a Top Workplace for Second Consecutive Year
Leave a Reply